DNA Repair and Prostate Cancer: A Field Ripe for Harvest

Alan H. Bryce; Oliver Sartor; Johann de Bono

doi:10.1016/j.eururo.2020.06.020

DNA Repair and Prostate Cancer: A Field Ripe for Harvest

Alan H. Bryce, Oliver Sartor, Johann de Bono

Hematology/Oncology

Research output: Contribution to journal › Editorial › peer-review

5 Scopus citations

Abstract

Recent data have revealed antitumor activity for four PARP inhibitors, two of which (olaparib and rucaparib) are approved by the US Food and Drug Administration for metastatic castrate-resistant prostate cancer with selected DNA repair defects. Additional clinical trials are in progress for talazoparib, veliparib, and niraparib. More progress can be anticipated in the near future.

Original language	English (US)
Pages (from-to)	486-488
Number of pages	3
Journal	European urology
Volume	78
Issue number	4
DOIs	https://doi.org/10.1016/j.eururo.2020.06.020
State	Published - Oct 2020

ASJC Scopus subject areas

Urology

Access to Document

10.1016/j.eururo.2020.06.020

Cite this

@article{8d0a10fa02a9495ab34308199057e9f8,

title = "DNA Repair and Prostate Cancer: A Field Ripe for Harvest",

abstract = "Recent data have revealed antitumor activity for four PARP inhibitors, two of which (olaparib and rucaparib) are approved by the US Food and Drug Administration for metastatic castrate-resistant prostate cancer with selected DNA repair defects. Additional clinical trials are in progress for talazoparib, veliparib, and niraparib. More progress can be anticipated in the near future.",

author = "Bryce, {Alan H.} and Oliver Sartor and {de Bono}, Johann",

note = "Publisher Copyright: {\textcopyright} 2020 European Association of Urology",

year = "2020",

month = oct,

doi = "10.1016/j.eururo.2020.06.020",

language = "English (US)",

volume = "78",

pages = "486--488",

journal = "European urology",

issn = "0302-2838",

publisher = "Elsevier",

number = "4",

}

TY - JOUR

T1 - DNA Repair and Prostate Cancer

T2 - A Field Ripe for Harvest

AU - Bryce, Alan H.

AU - Sartor, Oliver

AU - de Bono, Johann

PY - 2020/10

Y1 - 2020/10

N2 - Recent data have revealed antitumor activity for four PARP inhibitors, two of which (olaparib and rucaparib) are approved by the US Food and Drug Administration for metastatic castrate-resistant prostate cancer with selected DNA repair defects. Additional clinical trials are in progress for talazoparib, veliparib, and niraparib. More progress can be anticipated in the near future.

AB - Recent data have revealed antitumor activity for four PARP inhibitors, two of which (olaparib and rucaparib) are approved by the US Food and Drug Administration for metastatic castrate-resistant prostate cancer with selected DNA repair defects. Additional clinical trials are in progress for talazoparib, veliparib, and niraparib. More progress can be anticipated in the near future.

UR - http://www.scopus.com/inward/record.url?scp=85087404876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85087404876&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2020.06.020

DO - 10.1016/j.eururo.2020.06.020

M3 - Editorial

C2 - 32636098

AN - SCOPUS:85087404876

SN - 0302-2838

VL - 78

SP - 486

EP - 488

JO - European urology

JF - European urology

IS - 4

ER -

DNA Repair and Prostate Cancer: A Field Ripe for Harvest

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this